2018 Xtandi (enzalutamide; Pfizer/Astellas) Drug Analysis: An Androgen Receptor (AR) Signaling Inhibitor that Inhibits The AR at Three Distinct Points in the Signaling Pathway - ResearchAndMarkets.com

DUBLIN--()--The "Drug Analysis: Xtandi" drug pipelines has been added to ResearchAndMarkets.com's offering.

Xtandi (enzalutamide; Pfizer/Astellas) is an androgen receptor (AR) signaling inhibitor that inhibits the AR at three distinct points in the signaling pathway. Xtandi competitively inhibits binding of the androgens to the AR, inhibits AR nuclear translocation, and inhibits association of the AR with DNA. In preclinical studies, Xtandi was shown to provide a more complete suppression of the AR than Casodex (bicalutamide; AstraZeneca).

Market Data

List of Figures

Figure 1: Xtandi for prostate cancer - SWOT analysis

Figure 2: Drug assessment summary of Xtandi for prostate cancer

Figure 3: Drug assessment summary of Xtandi for prostate cancer

Figure 4: Xtandi sales for prostate cancer across the US, Japan, and five major EU markets, by country, 2017-26

List of Tables

Table 1: Xtandi drug profile

Table 2: Xtandi Phase III data in prostate cancer

Table 3: Xtandi Phase III trials in prostate cancer

Table 4: Xtandi sales for prostate cancer across the US, Japan, and five major EU markets, by country ($m), 2017-26

For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/sdmwrs/2018_xtandi?w=4

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Prostate Cancer Drugs

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Prostate Cancer Drugs